ORGO
Organogenesis Holdings IncNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$290.73M
P/E Ratio
15.07
EPS
$0.15
Beta
1.48
52W High
$7.08
52W Low
$2.21
50-Day MA
$3.21
200-Day MA
$4.27
Dividend Yield
—
Profit Margin
6.56%
Forward P/E
12.67
PEG Ratio
—
About Organogenesis Holdings Inc
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures and markets solutions for the advanced wound care and surgical and sports medicine markets in the United States. The company is headquartered in Canton, Massachusetts.
Fundamentals
| Revenue (TTM) | $564.17M |
| Gross Profit (TTM) | $426.65M |
| EBITDA | $74.98M |
| Operating Margin | 28.90% |
| Return on Equity | 9.04% |
| Return on Assets | 6.43% |
| Revenue/Share (TTM) | $4.45 |
| Book Value | $2.36 |
| Price-to-Book | 0.96 |
| Price-to-Sales (TTM) | 0.52 |
| EV/Revenue | 0.731 |
| EV/EBITDA | 4.97 |
| Quarterly Earnings Growth (YoY) | 555.00% |
| Quarterly Revenue Growth (YoY) | 78.10% |
| Shares Outstanding | $128.64M |
| Float | $57.98M |
| % Insiders | 47.61% |
| % Institutions | 54.55% |
Analyst Ratings
Consensus ($8.00 target)
2
BuyData last updated: 4/8/2026